Amarin upgraded by Jefferies with a new price target
$AMRN
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | Underweight | JP Morgan | |
| 10/25/2023 | $3.00 → $1.00 | Buy → Hold | Jefferies |
| 1/6/2023 | $1.30 → $3.00 | Hold → Buy | Jefferies |
| 5/6/2022 | Neutral → Underweight | JP Morgan | |
| 5/5/2022 | $10.00 → $3.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/5/2022 | $10.00 → $3.00 | Buy → Neutral | H.C. Wainwright |
| 5/4/2022 | Outperform → Market Perform | Northland Capital | |
| 2/16/2022 | $11.00 → $10.00 | Outperform | SVB Leerink |
10-Q - AMARIN CORP PLC\UK (0000897448) (Filer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
8-K - AMARIN CORP PLC\UK (0000897448) (Filer)
3 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of aspirin use in REDUCE-IT® reinforcing that icosapent ethyl significantly reduced cardiovascular (CV) events in high-risk patients. These findings highlight the importance of guideline-directed therapies and further validate the role of icosapent ethyl in comprehensive CV risk management in appropriate patients as studied in REDUCE-IT. This analysis was presented soon after the U.S. Food and Drug Administration (FDA) updated labeling for fenofibrate (fibrates) products that now
DUBLIN and BRIDGEWATER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced it will be presenting new findings at the American Heart Association's Scientific Sessions 2025 scheduled for November 7-10 in New Orleans, Louisiana. These new data supported by Amarin will further reinforce the robust efficacy of VASCEPA®/VAZKEPA® (icosapent ethyl) in cardiovascular risk reduction (CVRR) as well as highlight the pleiotropic mechanism of action of Eicosapentaenoic Acid (EPA). Data being featured at the AHA Scientific Sessions include new analyses from the REDUCE-IT study evaluating the c
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
4 - AMARIN CORP PLC\UK (0000897448) (Issuer)
JP Morgan resumed coverage of Amarin with a rating of Underweight
Jefferies downgraded Amarin from Buy to Hold and set a new price target of $1.00 from $3.00 previously
Jefferies upgraded Amarin from Hold to Buy and set a new price target of $3.00 from $1.30 previously
DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. "On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared priority to continue focusing on strategies to maximize shareholder value, make him a beneficial addition to the board at this time," said Odysseas Kostas, MD, Chairman of the Board. "I am eager to join the board and begin working with fellow directors and the s
DUBLIN and BRIDGEWATER, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Peter Fishman has been appointed as Chief Financial Officer for the Company, effective immediately. He will be responsible for leading Amarin's global finance organization and will report directly to the Company's Chief Executive Officer, Aaron Berg. Most recently, Mr. Fishman served as the Company's Global Controller and principal financial and accounting officer. "Pete brings tremendous experience to his new role at Amarin, including most recently as a trusted advisor to our leadership team serving as principal financial and accounting officer for the Company," said
-- Board Appoints Aaron Berg as President & CEO -- -- Patrick Holt to Step Down as President & CEO to Pursue Other Opportunities -- DUBLIN and BRIDGEWATER, N.J., June 04, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that the Company's Board of Directors has appointed Aaron Berg, currently Amarin's Executive Vice President and President of the U.S. Business, as President and Chief Executive Officer (CEO). The appointment of Mr. Berg follows the resignation of Patrick Holt as President & CEO of the Company. "On behalf of the Company's Board of Directors, I thank Pat for his contributions to Amarin, and I welcome working closely again with Aaron
Company completes transition to fully partnered commercialization model across all international markets Q3 2025 performance reflects initial impact of new approach to Europe, ongoing expansion of Rest-of-World demand, continued success in managing US market, and initial operating margin improvements following corporate rightsizingTargeting sustainable positive free cash flow in 2026 DUBLIN and BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care worldwide, today announced financial results for the third quarter of 2025. "With the reporting of Q3 2025 we usher in the next phase i
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular care, today announced that it will report third quarter 2025 financial results and conduct a conference call on Wednesday, October 29, 2025. The Company will issue a press release detailing its third quarter 2025 financial results in the pre-market hours, followed by a conference call with senior management at 8:00 a.m. ET. Information on how to participate is as follows. Access to the live call: Via telephone: Dial in within the United States: 877-545-0523 International dial in: 973-528-0016 Access Code: 459510 V
-- European Partnership with Recordati Established to Maximize VAZKEPA® in Europe; Global Corporate Restructuring Implemented with Anticipated $70 Million in Operating Expense Savings Over Next 12 Months -- -- Q2 2025 Financial Performance Reflects Incremental Progress for VASCEPA®/VAZKEPA® in Ex-U.S. Markets, and Continued Stability in U.S. Market -- -- Cash Position Sufficient to Fund Company's Future Growth Path -- DUBLIN and BRIDGEWATER, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced financial and operational results for the second quarter of 2025. "The strategic actions taken in the second quarter – our partnership with Recordati to a
SC 13G/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)
SC 13D/A - AMARIN CORP PLC\UK (0000897448) (Subject)